Cholangiocarcinoma (CCA) is a highly-aggressive malignancy arising from the biliary tree, characterized by a steady increase in incidence globally and a high mortality rate. Most CCAs are diagnosed in the advanced and metastatic phases of the disease, due to the paucity of signs and symptoms in the early stages. This fact, along with the poor results of the local and systemic therapies currently employed, is responsible for the poor outcome of CCA patients and strongly supports the need for novel therapeutic agents and strategies. In recent years, the introduction of next-generation sequencing technologies has opened new horizons for a better understanding of the genetic pathophysiology of CCA and, consequently, for the identification and evaluation of new treatments tailored to the molecular features or alterations progressively elucidated. In this review article, we describe the potential targets under investigation and the current molecular therapies employed in biliary tract cancers. In addition, we summarize the main drugs against CCA under evaluation in ongoing trials and describe the preliminary data coming from these pioneering studies.

Targeted therapies in cholangiocarcinoma: emerging evidence from clinical trials / Simile, Maria Maddalena; Bagella, Paola; Vidili, Gianpaolo; Spanu, Angela; Manetti, Roberto; Seddaiu, Maria Antonietta; Babudieri, Sergio; Madeddu, Giordano; Serra, Pier Andrea; Altana, Matteo; Paliogiannis, Panagiotis. - In: MEDICINA. - ISSN 1010-660X. - 55:2(2019), p. 42. [10.3390/medicina55020042]

Targeted therapies in cholangiocarcinoma: emerging evidence from clinical trials

Maria Maddalena, Simile;Paola, Bagella;Gianpaolo, Vidili;Angela, Spanu;Roberto, Manetti;Maria Antonietta, Seddaiu;Sergio, Babudieri;Giordano, Madeddu;Pier Andrea, Serra;Panagiotis, Paliogiannis
2019

Abstract

Cholangiocarcinoma (CCA) is a highly-aggressive malignancy arising from the biliary tree, characterized by a steady increase in incidence globally and a high mortality rate. Most CCAs are diagnosed in the advanced and metastatic phases of the disease, due to the paucity of signs and symptoms in the early stages. This fact, along with the poor results of the local and systemic therapies currently employed, is responsible for the poor outcome of CCA patients and strongly supports the need for novel therapeutic agents and strategies. In recent years, the introduction of next-generation sequencing technologies has opened new horizons for a better understanding of the genetic pathophysiology of CCA and, consequently, for the identification and evaluation of new treatments tailored to the molecular features or alterations progressively elucidated. In this review article, we describe the potential targets under investigation and the current molecular therapies employed in biliary tract cancers. In addition, we summarize the main drugs against CCA under evaluation in ongoing trials and describe the preliminary data coming from these pioneering studies.
Targeted therapies in cholangiocarcinoma: emerging evidence from clinical trials / Simile, Maria Maddalena; Bagella, Paola; Vidili, Gianpaolo; Spanu, Angela; Manetti, Roberto; Seddaiu, Maria Antonietta; Babudieri, Sergio; Madeddu, Giordano; Serra, Pier Andrea; Altana, Matteo; Paliogiannis, Panagiotis. - In: MEDICINA. - ISSN 1010-660X. - 55:2(2019), p. 42. [10.3390/medicina55020042]
File in questo prodotto:
File Dimensione Formato  
medicina-55-00042 (1).pdf

accesso aperto

Tipologia: Versione editoriale (versione finale pubblicata)
Licenza: Creative commons
Dimensione 1.06 MB
Formato Adobe PDF
1.06 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11388/219211
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 48
  • ???jsp.display-item.citation.isi??? 35
social impact